← Back to Search

Lactate Sensor

Evaluation of non-invasive lactate sensor for Hyperlactatemia

N/A
Waitlist Available
Led By Peter E Light, PhD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy and physically active volunteers
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial studied a non-invasive, painless device to measure lactate levels during intense leg exercise.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Only people who are healthy and able to be physically active can participate.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
That the lactate sensor under test is able track increase in interstitial lactate levels in exercising humans that follow the same time course as lactate values obtained from a commercial blood capillary lactate monitor.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Evaluation of non-invasive lactate sensorExperimental Treatment1 Intervention
To determine the efficacy and accuracy of the non-invasive lactate sensor
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lactate sensor (Lactisense)
2022
N/A
~10

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
883 Previous Clinical Trials
393,200 Total Patients Enrolled
Peter E Light, PhDPrincipal InvestigatorUniversity of Alberta

Media Library

Lactisense (Lactate Sensor) Clinical Trial Eligibility Overview. Trial Name: NCT05649358 — N/A
Hyperlactatemia Research Study Groups: Evaluation of non-invasive lactate sensor
Hyperlactatemia Clinical Trial 2023: Lactisense Highlights & Side Effects. Trial Name: NCT05649358 — N/A
Lactisense (Lactate Sensor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05649358 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment being accepted from participants over the age of thirty?

"Patient recruitment for this medical trial is limited to those over the age of 18 and under 45."

Answered by AI

Am I eligible to be a participant in this medical experiment?

"All potential participants must have hyperlactatemia and meet the age requirements of 18 to 45 years old in order to join this trial. The maximum number of accepted enrollees is 16 individuals."

Answered by AI

Are there any vacancies available to participate in this clinical trial?

"Per the data hosted on clinicaltrials.gov, this research endeavour is presently recruiting participants. The trial was originally posted on December 5th 2022 and has since been revised 12 days later."

Answered by AI

How many participants are enrolled in this clinical research?

"Indeed, the information on clinicaltrials.gov confirms that this trial is actively recruiting participants. The study was initially published on December 5th 2022 and has since been updated once more on December 13th of the same year. 16 patients are needed from 1 medical site for participation in this project."

Answered by AI
~4 spots leftby Mar 2025